Replies to post #195893 on Biotech Values

[DewDiligence]

More on ABT’s ABSORB stent—a WSJ writer labeled the results “mixed,” which I think is unduly harsh:

$ABT @joewalkerWSJ "Mixed"=too harsh an assessment,IMO. NI trial met 1ary endpt.NI shouldb good enuf4commrcl uptake given 0residual hardwre.

— Roy Friedman (@DewDiligence) October 12, 2015